Coldpack introduces Airliner insulation material
A new insulating film material for cost-effective temperature-controlled pharmaceutical transit packaging is being introduced in the UK by Coldpack.
Airliner preserves the temperature inside the pack. The inclusion of coolants, such as gel packs or dry ice, inside the Airliner can be used to implement an efficient and controlled cold-chain distribution. The Airliner maintains products in packs of up to 70 litres either at ambient temperatures, typical product temperatures (e.g. +2° to +8ºC for pharmaceutical products) or at -18ºC for frozen products.
Contents are said to be protected during transit for 48 hours, but extended cooling systems are also available offering up to120 hours" protection.
The pack can be supplied flat, reducing logistics and warehousing costs. In addition, a Pira International life cycle assessment found Airliner has 40-50% less impact on the environment than polystyrene.
You may also like
Trending Articles
-
You need to be a subscriber to read this article.
Click here to find out more.
You may also like
Logistics
Atelerix and Labskin team up to enable long-distance transport of temperature-sensitive skin models
The pair have forged an agreement to broaden access, streamline logistics and reduce variability associated with the temperature-sensitive shipping of 3D tissue models — without cryopreservation
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Packaging
Embracing sustainable change through labelling choice
Paavo Sillanpää, Senior Manager, Ecosystem Pharma and Healthcare, EMEIA, UPM Adhesive Materials, discusses the latest trends in pharmaceutical packaging and labelling and how producers can embrace future-focused solutions and sustainable options without compromising performance
Packaging
Sharp Services invests $100m to expand global sterile and packaging capacity across US and Europe
The investment will boost sterile fill/finish, injectable packaging and oral solid dose capacity across Sharp's US and European sites, strengthening its clinical and commercial manufacturing network to meet growing pharmaceutical demand